Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Therapeutic Solutions International Inc (OP: TSOI )

0.0004 +0.0002 (+100.00%)
Streaming Delayed Price Updated: 3:50 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Therapeutic Solutions International Inc

< Previous 1 2 3 Next >
Therapeutic Solutions International Advances Chronic Obstructive Pulmonary Disease Program by Identifying Novel B Regulatory Cell Mechanism of Action for JadiCell Universal Donor Adult Stem Cell
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Announces Plans to Initiate Breast Cancer Clinical Trial Using FloraStilbene™ Immune Stimulator Through Res Nova Bio Subsidiary
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Launches Veltmeyer Institute for Advanced Biologics
From Therapeutic Solutions International, Inc.
Via Business Wire
Res Nova Bio Leverages Immunological Similarities between Abortion Pill and Cancer Remission to Create Novel Immunotherapy
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Spin Off Res Nova Bio Announces Recruitment of President and Chief Executive Officer
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Spin-Off Campbell Neurosciences Provides Progress Update in Quest for Addressing Suicide as a Medical Condition
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Identifies Novel Cellular Marker Associated with Therapeutic Response to JadiCell Stem Cell Treatment
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Announces Antigen Specific Blockade of Pathological Immune Response in Multiple Sclerosis Model Using “Tattoo Gun” Immunization
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Announces Improvements in Autism, Amyotrophic Lateral Sclerosis and Schizophrenia Cases Treated by Veltmeyer Institute for Advanced Therapeutics
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Granted Broad Patent on Treatment of Neurodegenerative Conditions
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Launches Spin-Off Breathe Biologics Aimed at Curing Chronic Obstructive Pulmonary Disease (COPD)
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Spin-Off Res Nova Bio Collaborates with Veltmeyer MD Inc. to Provide Breast Cancer Patients Access to Novel Cancer Immunotherapy
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Granted Landmark United States Patent on Ability of QuadraMune® Nutraceutical to Repair Injured Brains
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Secures Financing to Complete Current Phase III Stem Cell Clinical Trial
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Spin-Off Company Campbell Neurosciences Announces Successful Preclinical Studies of CampbellCell for Treatment of Bipolar Disorder
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Develops Post JadiCell Maintenance Therapy for Chronic Obstructive Pulmonary Disease (COPD)
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Files with FDA to Expand ongoing Phase III Clinical Trial to Include All Causes of Acute Respiratory Distress Syndrome
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte™ on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Granted Emergency IND by FDA for Expanded Patient Access to JadiCell™ Universal Donor Stem Cell for COVID-19 ARDS Outside of Ongoing Phase III Clinical Trial
From Therapeutic Solutions International, Inc.
Via Business Wire
John Hopkin’s University Publishes Efficacy of QuadraMune™ Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory Studies
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Recruits Dr. Donald Banerji to Scientific Advisory Board
From Therapeutic Solutions International, Inc.
Via Business Wire
Therapeutic Solutions International Receives IND Number 28508 for Chronic Obstructive Pulmonary Disease Clinical Trial and Enters Binding Discussions with FDA for Initiation of Phase I/II Clinical Trial
From Therapeutic Solutions International
Via Business Wire
Phase III Lung Adult Stem Cell Company Announces and Files Patent on Leukine-Induced Myeloid Derived Suppressor Cells and JadiCell™ for Treatment of COPD
From Therapeutic Solutions International
Via Business Wire
Therapeutic Solutions International Files Investigational New Drug Application for Treatment of Chronic Obstructive Pulmonary Disease (COPD) Using JadiCell™ Universal Donor Adult Stem Cells
From Therapeutic Solutions International, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.